Security key
30054Y107
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 34,576,739
- Total 13F value
- $793,406,919
- Share change
- +7,040,143
- SEC-reported price per share
- $22.99
- Number of holders
- 84
- Value change
- +$167,246,545
- Number of buys
- 57
- Number of sells
- 21
- Shares outstanding
- 35,943,315
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
84
Top holders
10
EVMN full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Evommune, Inc. SEC filings
Evommune, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 30054Y107
Recent filing periods:
Ownership snapshot
Top reported holders of EVMN - Evommune, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
7. Cooperative Ua Lsp
Disclosed value leader
7. Cooperative Ua Lsp
Comparable rows
15/15
Latest evidence
17 Feb 2026
3/4/5
13D/G
13F
Lead comparable stake: 15%
13D/G row: 7. Cooperative Ua Lsp
Showing 1-6 of 15 holder rows.
Quick read
7. Cooperative Ua Lsp leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 7. Cooperative Ua Lsp's linked filing trail.
Comparable ownership
Top 5
7. Cooperative Ua Lsp
15%
Pivotal bioVenture Partners Fund ...
11%
RA CAPITAL MANAGEMENT, L.P.
9.7%
Isabel Verduyn van Weegen
15%
Robert Lorne Hopfner
9.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 7. Cooperative Ua Lsp |
3/4/5
13D/G
Director, 10%+ Owner · LSP 7 Cooperatieve U.A.
|
15%
from 13D/G
|
$147,438,166
5,288,313 shares
|
— | 17 Feb 2026 |
| Pivotal bioVenture Partners Fund I, L.P. |
13D/G
3/4/5
Nan Fung Group Holdings Limited · Director, 10%+ Owner
|
11%
|
$69,158,608
3,435,599 shares
|
$0 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13D/G
13F
Director · Company
|
9.7%
from 13D/G
|
$75,562,968
2,710,293 shares
|
— | 17 Feb 2026 |
| Isabel Verduyn van Weegen |
3/4/5
Director, 10%+ Owner
|
15%
|
$147,438,166
5,288,313 shares
|
— | 17 Feb 2026 |
| Robert Lorne Hopfner |
3/4/5
Director, 10%+ Owner
|
9.4%
|
$63,219,381
3,372,001 shares
|
+$17,350 | 19 Dec 2025 |
| EQT Fund Management S.a r.l. |
13F
Company
|
14%
|
$84,395,317
4,929,633 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
84
Shares
34,576,739
Rows available
84
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
59
Q1 2026 holders
84
Holder diff
25
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend